Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersDermatology Physician in Fountain Valley, CA
NPI: 1164656229Primary Practice Location
Tien Q Nguyen Inc
17271 Brookhurst St, Fountain Valley, CA
Primary Employer
TIEN Q NGUYEN INC
HQ Phone
Get M.D. Vivian's Phone Numberphone_androidMobile
Get M.D. Vivian's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
2010 - 2025
American Board of Dermatology
Dermatology
Vagelos College of Physicians and Surgeons
vagelos.columbia.edu
Medical School
Until 2009
University of California (Irvine)
Residency • Dermatology
2013 - 2017
Los Angeles County-Harbor-UCLA Medical Center
Internship • Internal Medicine
2009 - 2010
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99213Established patient office or other outpatient visit, typically 15 minutes | 57 | 69 |
| 2 | 96920Laser treatment (total area less than 250 sq centimeters) for inflammatory skin disease | 43 | 519 |
| 3 | 99203New patient outpatient visit, total time 30-44 minutes | 24 | 24 |
| 4 | 99214Established patient office or other outpatient visit, 30-39 minutes | 19 | 28 |
| 5 | 17000Destruction of skin growth | 17 | 20 |
Continuing medical educationAngiogenesis in cutaneous disease: Part II
A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results.
Authors: John Browning
Publication Date: 2020-07-24
Interleukin-33 antibody failed to demonstrate benefit in a phase II, double-blind, randomized, placebo-controlled study in adult patients with moderate-to-severe atopic dermatitis.
Authors: Vivian Laquer, Viviana Parra, Jean-philippe Lacour, Hidetoshi Takahashi, Jack Knorr, Angela Okragly, Douglas James, Jonathan Sims, Ching-yun Chang, Jeannie Chao, Paul Klekotka
Publication Date: 2021-05-26
Lead Sponsor: Eli Lilly and Company
Intervention / Treatment: DRUG: Placebo, DRUG: LY3375880
Lead Sponsor: Eli Lilly and Company
Intervention / Treatment: DRUG: Placebo, DRUG: LY3454738
Lead Sponsor: Eli Lilly and Company
Intervention / Treatment: DRUG: Placebo, DRUG: LY3041658